Biotech stocks were left for dead — written off after years of
brutal bear markets, failed trials, rising rates, and policy
shocks. But what if the sector is quietly waking up?
On this episode of In the Money with Amber Kanwar, Amber sits
down with Eden Rahim, Portfolio Manager at Next Edge Capital, to
unpack why one of the market’s most volatile and misunderstood
sectors may be entering a new bull cycle. Eden walks us through
biotech’s “nuclear winter” — from the 2011–2015 boom, to rolling
bear markets, to the post-COVID hangover that crushed even former
darlings like Moderna. He explains why extreme capitulation
readings — with companies trading below net cash and only 1% of
stocks above their 50-day moving average — signaled a
generational bottom. And since April, biotech has quietly been
outperforming the S&P 500… without the headlines.
But this is not a “buy the ETF and forget it” story. Eden breaks
down why biotech is the ultimate stock-picker’s market, how he
handicaps regulatory, clinical and commercial risk, and why he
focuses on post-Phase 2 companies where the odds shift
dramatically. He also addresses the new wild card investors must
navigate: shifting FDA goalposts and regulatory uncertainty.
In the Mailbag, Amber and Eden tackle stocks that aren’t exactly
household names for most investors. They break down Sarepta
(SRPT) and whether its dramatic collapse reflects broader gene
therapy risks. They discuss WELL Health (WELL) and why the stock
can lag even when analyst targets look optimistic. They also look
at DRI Healthcare (DRI.UN), the pharmaceutical royalty company
offering dividend-paying exposure to drug innovation, and whether
its leveraged royalty model is a smarter way to get biotech-like
upside with cash flow. Plus, they touch on why Canadian biotech
companies often migrate south — and what that means for investors
hunting for overlooked opportunities.
In Pro Picks, Eden shares three
high-conviction ideas: Alpha Cognition (ACOG), a newly approved
Alzheimer’s therapy with improved tolerability and strong
commercial runway; ClearPoint Neuro (CLPT), a brain-delivery
platform embedded across dozens of gene therapy programs; and
NeurAxis (NRXS), a small-cap device company targeting gut-brain
disorders with expanding reimbursement tailwinds. Volatile,
under-the-radar — and potentially early leaders in a new biotech
cycle.
And don’t forget to vote on your favourite In the Money swag
ideas! Head to: https://www.surveymonkey.com/r/XKGW2HT
Timestamps
00:00 trailer
02:15 intro
04:50 What’s it been like to be a biotech investor in
recent years?
07:10 What happened in the biotech sector?
08:50 Covid & biotech
11:20 How biotech is different from other sectors
15:50 Biotech has been outperforming the S&P 500
17:50 It comes down to stock picking
23:10 The regulatory environment is now a wild
card
31:50 ITM Mailbag: Sarepta Therapeutics (SRPT)
38:30 WELL health (WELL)
41:50 DRI Healthcare Trust (DHT.UN)
45:50 Eden’s Pro Picks (ACOG, CLPT, NRXS)
Sponsors
For over 25 years, Raymond James has been helping Canadians
achieve their financial goals. Visit https://raymondjames.ca
today to discover how you can live a life well planned.
To explore BMO ETF tools, head to https://www.bmoetfs.com and
check out the Tools section.
Pro Picks is brought to you by ATB Financial. Visit
https://ATB.com/inthemoney for more information
Links
https://inthemoneypod.com/
https://instagram.com/inthemoneypod
https://facebook.com/profile.php?id=61569721774740
https://twitter.com/inthemoneypod
https://tiktok.com/@inthemoneypod
questions@inthemoneypod.com
DISCLAIMERS
The information provided in this podcast is for informational
purposes only and does not constitute financial, investment, or
professional advice.The views expressed by the host and guests
are their own and do not necessarily reflect the opinions of any
organization or company. The host and guests may maintain
positions in any securities discussed on the podcast. Always
consult with a qualified financial advisor or professional before
making any investment decisions. In this episode we discuss
Pfizer which is a stock Amber owns.
In the Money delivers expert stock picks, actionable ideas, and
timely money management tips. Hosted by business journalist Amber
Kanwar, each episode features interviews with top portfolio
managers who suggest ways to achieve good returns. Covering
everything from ETFs and Canadian stocks to global investing
trends, dividend strategies, and risk management, this show is
made for DIY investors, stock market enthusiasts, and anyone
looking to sharpen their financial strategy.
Contact: questions@inthemoneypod.com
#IntheMoney #Investing #StockMarket #CanadianInvesting
#FinancialNews
Kommentare (0)
Melde dich an, um einen Kommentar zu schreiben.